Odyssey Therapeutics is a company developing novel medicines for the treatment of cancer and autoimmune diseases.

Dr. Leiden has served as a member of Vertex’s board of directors since 2009 and as Chairman since 2012. He was President and CEO from 2012-2020. Under his leadership, Vertex delivered the first and only precision medicines to treat the underlying cause of cystic fibrosis (CF). During his tenure as CEO he also built a pipeline of transformative medicines for serious diseases including pain, ApoL1 mediated kidney disease, Type I Diabetes, Sickle Cell Disease and Beta-Thalasemia. Dr. Leiden established a collaboration with Crispr Therapeutics that resulted in the first potentially curative human gene editing approach for people with Sickle Cell Disease and Beta Thalasemia. He also led the acquisition of Semma that resulted in the first potentially curative stem cell mediated therapy for patients with Type I Diabetes. Under his leadership the market capitalization of Vertex increased from approximately $9B to more than $63B.Dr. Leiden also cares deeply about inspiring and equipping under-resourced students and young women to become the next generation of scientific leaders. He established a signature program at Vertex to enhance science, technology, engineering, art and math (STEAM) education among students in Vertex's local communities, including an on-site Learning Lab, mentorship programs, internships and college scholarships. In 2017, Vertex announced a sustained corporate giving commitment of $500 million over the next 10 years, of which $50 million is focused on STEAM education.

BrightInsight provides the leading global SaaS platform for biopharma and medtech regulated digital health solutions. BrightInsight’s vision is to transform patient outcomes globally by bringing the power of digital technology to healthcare, and we work every day to achieve this by accelerating regulated digital health innovation for our customers through our scalable medical-grade SaaS platform.

Casana creates breakthrough technology that unobtrusively checks a person’s health status at home, providing timely clinical notifications to caregivers and clinicians, and peace of mind to our elderly and those managing chronic disease. Casana was founded in July of 2018, and is a spin-off from the Rochester Institute of Technology (RIT) in partnership with the University of Rochester Medical Center (URMC).

Tmunity Therapeutics is a biotechnology company developing novel T-cell immunotherapies to treat solid tumors.

From 2006 to 2011, Dr. Leiden was a Managing Director of Clarus Ventures, a life sciences venture capital firm. There he was dedicated to developing new treatments through the creation and funding of innovative biotech companies.

From 2000 to 2006, Dr. Leiden served as President and Chief Operating Officer and Chief Scientific Officer at Abbott Laboratories where he had responsibility for running Abbott’s global pharmaceuticals business. While at Abbott, Dr. Leiden led the development and launch of multiple breakthrough medicines, including HUMIRA® (adalimumab) for rheumatoid arthritis and other autoimmune diseases and KALETRA® (lopinavir/ritonavir) for HIV infection.

In 1999, Dr. Leiden was appointed the Elkin R. Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of Medicine at the Harvard Medical School.

Dr. Leiden was the Chief of Cardiology, the Rawson Professor of Medicine and Pathology, and an Attending Physician at the University of Chicago Medical Center, where he led a team of more than 40 cardiologists and 50 scientists as the Director of the Cardiovascular Research Institute.

Dr. Leiden was an Attending Physician and Assistant/Associate Investigator of the Howard Hughes Medical Institute at the University of Michigan in Ann Arbor, MI. There, he directed a research lab focused on the molecular genetics of heart and blood development, as well as gene therapy.